Greetings and welcome to the Ekso Bionics' Third Quarter 2017 Financial Results Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded. For opening remarks, I'll now turn the call over to David Carey of Lazar Partners. Thank you, David, you may begin.

Thank you, Devin. And thank you all for participating in today's call. Joining me from Ekso Bionics are Tom Looby, President and Chief Executive Officer; and Max Scheder-Bieschin, Chief Financial Officer. Earlier today, Ekso Bionics released financial results for the quarter and 9 months ended September 30, 2017. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that is not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements including without limitation are examination of historical operating trends and our future financial expectations are based upon management's current estimates and various assumptions. These statements involve material risk and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and descriptions of the risks and uncertainties associated with our business, please see our filings with the Securities and Exchange Commission. Ekso disclaims any intention or obligation except as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the broadcast today, November 8, 2017. I will now turn the call over to Thomas Looby. Tom?

Thank you, David and thanks to everyone, for participating on today's call. Ekso Bionics is operating at the nexus of technology and healthcare and we believe that we're strongly positioned to address critical needs in the rehabilitation market. We're pleased that in Q3, 2017 we generated a 10% increase in total revenues and a 20% increase in the medical business as compared to Q3, 2016. In addition, the success of our recent fund raising gives us significant financial resources to bridge the gap between the promise of our technology and the realization of its potential in the rehabilitation market. We made important progress on the third quarter in strengthening the resources that will allow us to achieve this critical objective in the month ahead and we're very pleased with the feedback that we're receiving from customers and prospects about the benefits that our products provide to patients in healthcare facilities. During today's call I'll review highlights from the third quarter and share several of the success stories that our customers have reported and Max will provide an overview of our third quarter results. We successfully completed $34 million rights offering, $20 million of which was underwritten by Puissance Capital. Proceeds from this offering will support our ongoing efforts to advance the clinical, sales and marketing initiatives to accelerate the adoption of Ekso products in the rehabilitation market. Proactively pursue lower cost manufacturing and broaden our footprint to Asia. We believe the Asian market provides significant opportunities in both medical and industrial segments and we're actively evaluating potential routes to bringing Ekso products and technologies to countries throughout the region. Before we continue, I'd like to thank all of our existing shareholders who participated in this right offering. We also strengthened our leadership team to the appointment of Christian Babini as…

Thanks Tom. Total reported revenue for the quarter ended September 30, 2017 was $1.6 million including approximately $1.3 million in medical device revenue and $300,000 in industrial sales. These results are 10% above the $1.5 million in revenue generated in Q3, 2016, 20% above the $1.1 million in medical revenue and 25% below the $400,000 in industrial sales. We shipped 11 net new units to eight customers including one new rented unit. In addition, two rented units that shipped in prior quarters were converted to a sale during this quarter. We now have in the field 240 sold units plus 15 rented units. Gross profit for the quarter was $500,000 compared to $400,000 for the same quarter last year. This is an increase in gross margin to 34% from 25% during the same period in 2016 driven primarily by placing more units in the field and lower service costs. Operating expenses for the third quarter of 2017 were $7.6 million as compared to $7.3 million for the same period 2016. This increase was due primarily to our continued investment in the commercialization of our medical devices for rehabilitation and our exoskeleton offerings for industrial applications and an increase in clinical research activity. Net loss for the third quarter was $6.3 million for a 46% reduction from the loss of $11.5 million for the third quarter of last year. Cash on hand at September 30, 2017 was $33.4 million [technical difficulty] compared to $16.8 million at December 31, 2016. The increase in cash on hand [technical difficulty] refinanced rights offering completed in the third quarter of 2017. For the nine months ended September 30, 2017 the company used $25.6 million of cash in operations compared to $20.6 million for the nine months ended September 30, 2016. Please see our 10-Q filed earlier today for further details regarding the quarter and nine months ended September 30, 2017. I will now turn the call back to Tom.

Thanks Max. We're making solid progress in building and communicating the value proposition for our medical and industrial products and our third quarter achievements are important steps on the road to realizing the value of Ekso's technologies. As I shared at the outset, Ekso Bionics is at the nexus of unique technology and a significant accelerating healthcare need. Predicting when the standard of rehabilitative care will move to robotic tools like the EksoGT is not easy, yet current trends give us high confidence this transition will happen, such a potential paradigm shift and standard of care would represent a huge breakthrough for those recovering from stroke and similar types of paralysis and would help to restore and advance the health of an ageing society. The changing dynamic of rehabilitation paradigms creates a significant opportunity for Ekso Bionics to secure our position as the leader in exoskeleton technology. Today our balance sheet is the strongest that it's ever been, and we're focused on leveraging our financial resources to identify and pursue options that will enable us to build a sustainable business model. With the investment by Puissance and the fully financed rights offering from September we're strongly positioned to pursue a joint venture that provides a path to lowering our costs and take actions to prudently and efficiently further the adoption of our technology in both the medical and industrial markets in the United States and abroad. Our vision is to use exoskeleton technologies to help humanity and this requires nurturing and enabling change within the rehabilitation ecosystem in a way that allows its members to see beyond the way that they've grown accustomed to providing patient care. Seeing a demonstration of the EksoGT either in person or online makes it clear that this technology has the potential to transform human…

[Operator Instructions] our first question comes from the line of Bruce Nudell with SunTrust Robinson Humphrey. Please proceed with your question.

This is Matt in for Bruce. I guess the first question that 3Q results. could you give us any more color on the unit trends it looks like there were down sequentially a little bit, would you characterize this as normal summer seasonality or [indiscernible] than you expected?

I think you hit the nail in the head. We know that in Europe for example lot of the countries go on long holidays Q3 tends to be a little bit softer because of that. I think more importantly this is a capital good and it's in a new market and it takes some time for the decision making to take place at these clinics. Sometimes they fall in one quarter and sometimes they fall in the next. But more than just - I know the unit placement is sort of an easy thing for people to latch onto, but we're seeing lot of other indicators that we're getting lot of confidence moving forward including the pipeline building both in the US and EMEA. Some of the changes that we've made on both coasts so to speak, I think are really helping us get better visibility to what that pipeline is going to look like in the future.

Got it and so any color you can provide I guess on expected unit growth over the next few quarters for adding color on the pipeline and how that might influence placements [ph]?

Yes, I'll let Max chime in, maybe with a little bit more maybe detailed. But let me just talk about some broad changes here. We mentioned Christian a couple of times during our prepared comments and he comes by way of two or three different companies that have tried to do and succeeded in doing what we're doing which is innovating in area of medicine with robotics. And I'm just very pleased that in the first three weeks of his tenure with us. It is being just a radical change and how we approach it. Not to say that we were doing anything incorrect before, but I think where we've matured with some of our value proposition. He's coming in at perfect time to really leverage that value proposition and one of the key changes is our focus on the C-suite and hospitals. Of course, patient families and clinicians they see the change that we're making in the lives of patients every single day, every single step. I think what we need to do is to be very clear with the leadership in these clinics, in these hospitals that when they recruit a new patient because they're recruiting them to Ekso Bionics and the EksoGT that is a very good profitable revenue stream for these clinics. They want to fill these beds and when you can articulate that message very clearly to these leaders. I think we're going to see the uptick in our sales there.

Further to what Tom was talking about regarding the quarter, Matt. We're halfway through the quarter, we're very positive about what the end of the year looks like. Tom mentioned the growth in the pipeline. I think the other positive trend of note is, the continued rental conversions, of rentals that we have in the field, so we have a good outlook and good potential for those units. Tom talked about Christian's efforts and the impact he's had. I think Matthias has gone through a big change in EMEA. He's changed out his entire sales and marketing team, now that's behind him and I think you'll start seeing traction from those efforts as well in this quarter and then in the ensuing quarters in 2018.

Got it. That's great. And then I guess just shifting gears to Asia. Could you give us any more color there? What markets geographically are most important to you and kind of could that be a major commercial impact over the next 12 to 24 months for you guys?

Well you ask a lot in that question and I'm glad you asked about 12 to 24 months. We started to talk about our research in Asia a few quarters ago. And we say research because I think we've been very prudent that we wanted to have investment lead our penetration into that market and with the rights offering behind us and with our Puissance investing, we're very much - we got the balance sheet to now look in that area. And more than that, Puissance brings with them some expertise and maybe helping us evaluate the Chinese market in particular. So, few things are of interest for us in Asia, certainly as a commercial outlet for our products and we know that, that his huge. They have an ageing population, they have sort of nascent [ph] physical therapy as a career, their clinics are kind of all over the range, so we know that they're going to have to do two things over in that area of the world, hire physical therapist and train them and use technologies to leverage relatively scarce resources whether that's home caregivers or professional caregivers. They're going to need technologies like the EksoGT to be able to do that, so a commercial outlet is one thing of interest, but also the access to talent, operations maybe even supply all these things we're going to explore. But Asia's also a bit bigger than China, so while we're looking specifically into China we're also being I think proper in looking at other areas in Asia where they have maybe faster regulatory processes but also attractive healthcare economies. So, we haven't pulled the trigger yet with these plans, we're certainly in the planning phase. But we're going to make sure that whatever plan we put forth. The revenue potential cost and the cost base are going to be quite closely tethered to each other. So, we're going to operate in this new region I think in a very prudent way.

Right and then just one last one for me. You've put out the press release during the quarter on the Genesis Rehab opportunity, can you give any more color on sort of the data that you're looking to compile there and would be might see those results?

While we designed a pretty elaborate prospective multi-centered study with the WISE study, this one actually came to us. It also took a while to develop but this one is about all of those patients that go into skilled nursing facilities for various reasons and many of them not about stroke or spinal cord injury, but can these technologies help people create steps and rehabilitate or in essence not lose some capability because they're sitting in a hospital bed for long periods of time. So that really is sort of the general lay of the land with regard to these pilot studies. What I've been encouraged about I think it's in the last quarter just the enthusiasm that we're hearing from these centers. We have started discussions that as you know, sometimes things take time, but we did this maybe about a year ago. I think that really the interest is accelerated in these pilot side studies and I hope that it creates not just a fan base from these two clinics but also data that we can use maybe to expand our label in the future.

Matt one of the things specific to the skilled nursing facilities. Do they tend to see the through the physical rehabilitation, their gait process peaking relatively early and what we're hoping to show and see is that with the SmartAssist software where we have this capability of detecting someone's weakness and then the device complements that? What we're seeing initially anecdotally and then hopefully continued overtime. Is that our device allows somebody to continue to improve their gait, allowing them to continue with gait therapy and hopefully being released in much better shape than they were or have been to-date with current standard of care.

And I would just, as a personal note I had a loved one who suffered a heart attack four or five years ago and went into a skilled nursing facility for a number of months and they didn't have exoskeletons at this time. I think that from a personal point of view, if this technology been around then I think the rehabilitation would have taken a lot less time, it would have greater outcomes at the end. Of course, we need data to kind of convince others of that as well, but these studies are certainly giving us some promise.

Great. Thanks so much for taking the questions. I'll get back in queue.

At this time there are no more questions. I'd like to turn the call back over to Tom Looby for closing remarks.

Thank you all for joining us today. As we move into the last quarter of 2017 I believe strongly that we're positioned for both near and long-term success. The recent additions to our leadership team and financial resources, our powerful assets for ensuring that we have a strategy in place to achieve our goals and the personal [indiscernible] capital to execute that strategy with precision and efficiency. We also have the products, technologies and innovative potential to meet the needs of an ageing population here in the United States and developed countries around the world. Our mission at Ekso Bionics is to innovative with disruptive technologies that allow people to rethink the physical limitations of the human body and achieve the remarkable at home and at work. We look forward to sharing our continued progress in this mission with you in the months ahead.

This concludes today's call. All parties may now disconnect.